425 related articles for article (PubMed ID: 34541920)
21. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures.
Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA
Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083
[TBL] [Abstract][Full Text] [Related]
22. Real-world utilization of andexanet alfa.
Brown CS; Scott RA; Sridharan M; Rabinstein AA
Am J Emerg Med; 2020 Apr; 38(4):810-814. PubMed ID: 31870672
[TBL] [Abstract][Full Text] [Related]
23. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.
Huttner HB; Gerner ST; Kuramatsu JB; Connolly SJ; Beyer-Westendorf J; Demchuk AM; Middeldorp S; Zotova E; Altevers J; Andersohn F; Christoph MJ; Yue P; Stross L; Schwab S
Stroke; 2022 Feb; 53(2):532-543. PubMed ID: 34645283
[TBL] [Abstract][Full Text] [Related]
24. Prothrombin complex concentrates and andexanet for management of direct factor Xa inhibitor related bleeding: a meta-analysis.
Luo C; Chen F; Chen YH; Zhao CF; Feng CZ; Liu HX; Luo DZQ
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2637-2653. PubMed ID: 33829451
[TBL] [Abstract][Full Text] [Related]
25. Co-administration of Four-Factor Prothrombin Complex Concentrate With Andexanet alfa for Reversal of Nontraumatic Intracranial Hemorrhage.
Pathan S
Hosp Pharm; 2024 Aug; 59(4):394-406. PubMed ID: 38919755
[No Abstract] [Full Text] [Related]
26. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
[TBL] [Abstract][Full Text] [Related]
27. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds.
Keinath JJ; Lekura J; Hauser CD; Bajwa MK; Bloome ME; Kalus JS; Jones MC
J Thromb Thrombolysis; 2023 Aug; 56(2):315-322. PubMed ID: 37289371
[TBL] [Abstract][Full Text] [Related]
28. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
[TBL] [Abstract][Full Text] [Related]
29. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
[TBL] [Abstract][Full Text] [Related]
30. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
31. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series.
Bradshaw PG; Keegan S; Foertsch M; Yang GL; Ngwenya LB; Srinivasan V
J Thromb Thrombolysis; 2022 Aug; 54(2):295-300. PubMed ID: 35507109
[TBL] [Abstract][Full Text] [Related]
32. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
[TBL] [Abstract][Full Text] [Related]
33. Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.
Dobesh PP; Fermann GJ; Christoph MJ; Koch B; Lesén E; Chen H; Lovelace B; Dettling T; Danese M; Ulloa J; Danese S; Coleman CI
Res Pract Thromb Haemost; 2023 Aug; 7(6):102192. PubMed ID: 37753225
[TBL] [Abstract][Full Text] [Related]
34. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study.
Singer AJ; Concha M; Williams J; Brown CS; Fernandes R; Thode HC; Kirchman M; Rabinstein AA
West J Emerg Med; 2023 Sep; 24(5):939-949. PubMed ID: 37788035
[No Abstract] [Full Text] [Related]
36. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants.
Gómez-Outes A; Alcubilla P; Calvo-Rojas G; Terleira-Fernández AI; Suárez-Gea ML; Lecumberri R; Vargas-Castrillón E
J Am Coll Cardiol; 2021 Jun; 77(24):2987-3001. PubMed ID: 34140101
[TBL] [Abstract][Full Text] [Related]
37. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
38. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Giovino A; Shomo E; Busey KV; Case D; Brockhurst A; Concha M
Clin Neurol Neurosurg; 2020 Aug; 195():106070. PubMed ID: 32679541
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of oral factor Xa inhibitor-associated extracranial bleeding reversal with andexanet alfa.
Nederpelt CJ; Naar L; Sylvester KW; Barra ME; Roberts RJ; Velmahos GC; Kaafarani HMA; Rosenthal MG; King DR
J Thromb Haemost; 2020 Oct; 18(10):2532-2541. PubMed ID: 32738161
[TBL] [Abstract][Full Text] [Related]
40. Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors - Individual patient data analysis of ANNEXA-4 and TICH-NOAC.
Siepen BM; Polymeris A; Shoamanesh A; Connolly S; Steiner T; Poli S; Lemmens R; Goeldlin MB; Müller M; Branca M; Rauch J; Meinel T; Kaesmacher J; Z'Graggen W; Arnold M; Fischer U; Peters N; Engelter ST; Lyrer P; Seiffge D
Int J Stroke; 2024 Jun; 19(5):506-514. PubMed ID: 38264861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
